Pulmonary Embolism Pipeline Analysis: 05+ Companies are working to improve the Treatment of Space

DelveInsight's, "Pulmonary Embolism Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Pulmonary Embolism Pipeline Report
• DelveInsight's Pulmonary Embolism Pipeline report depicts a robust space with 05+ active players working to develop 05+ pipeline therapies for Pulmonary Embolism.
• The leading Pulmonary Embolism Companies are working such as Supergene, Servier, Daiichi Sankyo Company, Tasly Pharmaceuticals, Yuhan, and others.
• Promising Pulmonary Embolism Pipeline therapies such as Recombinant staphylokinase, Recombinant human prourokinase, and others.
• The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Embolism.

Recent Breakthroughs of the Pulmonary Embolism Treatment Landscape
• Recombinant human prourokinase is being developed by Tasly Pharmaceuticals, for the treatment of myocardial infarction, stroke and pulmonary embolism. Human pro-urokinase, is a single chain structure urokinase-type plasminogen activator, prepared via recombinant DNA technology. The drug is in Phase II clinical studies for the treatment of pulmonary embolism.
• Recombinant staphylokinase contains Forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of Pulmonary Embolism.

Request a sample and discover the recent advances in Pulmonary Embolism Medication @ https://www.delveinsight.com/sample-request/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Embolism Overview
A Pulmonary Embolism is a blockage in the pulmonary artery, which supplies the blood to the lungs. Although Pulmonary Embolism can arise from anywhere in the body, most commonly it arises from the calf veins. It usually happens when a blood clot breaks loose and travels through the bloodstream to the lungs. Symptoms of a Pulmonary Embolism include sudden shortness of breath, pain in and around the chest and coughing. Pulmonary Embolism is commonly detected through the following tests: Computed tomography (CT) scan, Lung scan, Blood tests (including the D-dimer test), Pulmonary angiogram, Ultrasound of the leg, Magnetic resonance imaging (MRI) of the legs or lungs.

Medicines like anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming; thrombolytics are medicines used to dissolve blood clots. A vena cava filter may be used in some people who cannot take blood thinners. Catheter-assisted thrombus removal procedure uses a flexible tube to reach a blood clot in your lung and a tool is inserted in the tube to break up the clot or to deliver medicine through the tube.

Pulmonary Embolism Emerging Drugs
• Recombinant staphylokinase: Supergene
• Recombinant human prourokinase: Tasly Pharmaceuticals

Pulmonary Embolism Pipeline Therapeutics Analysis
There are approx. 5+ key companies which are developing the therapies for Pulmonary Embolism. The companies which have their Pulmonary Embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

DelveInsight's Pulmonary Embolism Pipeline report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Learn more about the emerging Pulmonary Embolism pipeline therapies @ https://www.delveinsight.com/sample-request/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pulmonary Embolism Pipeline Insight Report
• Coverage- Global
• Pulmonary Embolism Pipeline Assessment by Product Type
• Pulmonary Embolism Pipeline Assessment by Stage and Product Type
• Pulmonary Embolism Pipeline Assessment by Route of Administration
• Pulmonary Embolism Pipeline Assessment by Stage and Route of Administration
• Pulmonary Embolism Pipeline Assessment by Molecule Type
• Pulmonary Embolism Pipeline Assessment by Stage and Molecule Type
• Pulmonary Embolism Companies- Supergene, Servier, Daiichi Sankyo Company, Tasly Pharmaceuticals, Yuhan, and others.
• Pulmonary Embolism Pipeline therapies- Recombinant staphylokinase, Recombinant human prourokinase, and others

Table of Content
1. Introduction
2. Executive Summary
3. Pulmonary Embolism: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pulmonary Embolism - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Pulmonary Embolism Collaboration Deals
9. Late Stage Products (Phase III)
10. Recombinant staphylokinase: Supergene
11. Mid Stage Products (Phase II)
12. Recombinant human prourokinase: Tasly Pharmaceuticals
13. Early Stage Products (Phase I)
14. YHP1906: Yuhan
15. Preclinical/Discovery Stage Products
16. Drug name: Company name
17. Inactive Products
18. Pulmonary Embolism Key Companies
19. Pulmonary Embolism Key Products
20. Pulmonary Embolism- Unmet Needs
21. Pulmonary Embolism- Market Drivers and Barriers
22. Pulmonary Embolism- Future Perspectives and Conclusion
23. Pulmonary Embolism Analyst Views
24. Pulmonary Embolism Key Companies
25. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
1. How many companies are developing Pulmonary Embolism drugs?
2. How many Pulmonary Embolism drugs are developed by each company?
3. How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Embolism?
4. What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Embolism therapeutics?
5. What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
6. What are the clinical studies going on for Pulmonary Embolism and their status?
7. What are the key designations that have been granted to the emerging drugs?

Got queries? You may connect with us @ https://www.delveinsight.com/report-store/pulmonary-embolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.